Mesoblast is the name most biotech investors recognize when it comes to stem cell therapies for back pain.
But what if I told you a rival exists — with stronger early data, a faster regulatory track, and zero reliance on donor tissue?
It’s true. This microcap has a therapy already in a pivotal Phase 2 trial… showing huge improvement in pain and mobility for nearly 70% of patients from a single injection.
Even better? The FDA awarded it Fast Track status — a green light few companies ever receive.
And here’s the kicker: while an approved company like Mesoblast trades at a $1.46 billion valuation…
This company trades at just $12 million.
That’s a 114x discount — despite clinical, manufacturing, and IP advantages.
Analysts are starting to wake up. The chart’s forming a breakout wedge. And with a float under 5 million shares, the next move could be pivotal.